Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference
August 29 2018 - 7:00AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer biology, announces
that the Company will present at the 20th Annual H.C. Wainwright
Global Investment Conference on September 5 at 10:50 a.m. EDT, in
Astor Suite A at the St. Regis Hotel in New York. Spiro Rombotis,
President & Chief Executive Officer, will provide an overview
of the Company and progress in key programs.
A live webcast of the presentation will be
available through the Company's corporate website:
www.cyclacel.com. The webcast will be archived for 90 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company developing innovative medicines based on cancer biology.
Cyclacel's transcriptional regulation program is evaluating CYC065,
a dual CDK2/9 inhibitor, in patients with advanced cancers. The DNA
damage response program is evaluating a sequential regimen of
sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive
patients with advanced solid cancers. Cyclacel's strategy is to
build a diversified biopharmaceutical business focused in
hematology and oncology based on a pipeline of novel drug
candidates. For additional information, please visit
www.cyclacel.com.
Forward-looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy,
safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsCompany:
Paul McBarron, (908)
517-7330, pmcbarron@cyclacel.comInvestor Relations: Russo
partners LLC, Alexander Fudukidis, (646) 942-5632,
alex.fudukidis@russopartnersllc.com
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024